Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07129252 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
A Phase 1 study of Neuroendocrine Tumors and Neuroendocrine Neoplasm, sponsored by Crinetics Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT07129252 is a Phase 1 study of Neuroendocrine Tumors and Neuroendocrine Neoplasm that is actively recruiting participants, run by Crinetics Pharmaceuticals. The registered enrollment target is 150 participants, below the 177-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (15% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT07129252, a Phase 1 study of Neuroendocrine Tumors and Neuroendocrine Neoplasm, is actively recruiting participants, sponsored by Crinetics Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.
Conditions Studied
Interventions
- DRUG CRN09682
Study Locations (20)
California
- Crinetics Study Site - Duarte
- Crinetics Study Site - Newport Beach
- Crinetics Study Site - Orange
- Crinetics Study Site - San Francisco
Texas
- Crinetics Study Site - Austin
- Crinetics Study Site - Houston
- Crinetics Study Site - Irving
Other
- Crinetics Study Site - Barcelona
- Crinetics Study Site - Barcelona
- Crinetics Study Site - Madrid
Virginia
- Crinetics Study Site - Charlottesville
- Crinetics Study Site - Fairfax
Colorado
- Crinetics Study Site - Denver
Connecticut
- Crinetics Study Site - New Haven
Georgia
- Crinetics Study Site - Atlanta
Kentucky
- Crinetics Study Site - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-11-26 |
| Est. Completion | 2029-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07129252
The ClinicalTrials.gov registry entry for NCT07129252 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 177-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (15% lower). The listed sponsor is Crinetics Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 1 intervention - of which CRN09682 is the first listed.
NCT07129252 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Texas, Other.
Frequently Asked Questions
What is clinical trial NCT07129252 about?
NCT07129252 is a clinical study titled "A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors". This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD i...
What is the current status of trial NCT07129252?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2025-11-26. Estimated completion is 2029-08.
What conditions does trial NCT07129252 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors, Neuroendocrine Neoplasm, SST2-positive Neuroendocrine Neoplasms.
What interventions are being tested in trial NCT07129252?
The interventions under investigation include: CRN09682 (DRUG).
Who is sponsoring clinical trial NCT07129252?
This trial is sponsored by Crinetics Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07129252 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RECRUITING · Phase 1
-
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
RECRUITING · Phase 1
-
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
RECRUITING · Phase 1
-
177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.